276 related articles for article (PubMed ID: 36460333)
1. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
[TBL] [Abstract][Full Text] [Related]
2. Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model.
Koellhoffer EC; Mao C; Beiss V; Wang L; Fiering SN; Boone CE; Steinmetz NF
Mol Pharm; 2022 Feb; 19(2):592-601. PubMed ID: 34978197
[TBL] [Abstract][Full Text] [Related]
3. Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy.
Beiss V; Mao C; Fiering SN; Steinmetz NF
Mol Pharm; 2022 May; 19(5):1573-1585. PubMed ID: 35333531
[TBL] [Abstract][Full Text] [Related]
4. In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.
Murray AA; Wang C; Fiering S; Steinmetz NF
Mol Pharm; 2018 Sep; 15(9):3700-3716. PubMed ID: 29798673
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Fate of Cowpea Mosaic Virus In Situ Vaccine: Biodistribution and Clearance.
Affonso de Oliveira JF; Chan SK; Omole AO; Agrawal V; Steinmetz NF
ACS Nano; 2022 Nov; 16(11):18315-18328. PubMed ID: 36264973
[TBL] [Abstract][Full Text] [Related]
6. Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.
Wang C; Beiss V; Steinmetz NF
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375592
[TBL] [Abstract][Full Text] [Related]
7.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
9. Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy.
Gautam A; Beiss V; Wang C; Wang L; Steinmetz NF
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575893
[TBL] [Abstract][Full Text] [Related]
10. Inactivated Cowpea Mosaic Virus for In Situ Vaccination: Differential Efficacy of Formalin vs UV-Inactivated Formulations.
Jung E; Mao C; Bhatia M; Koellhoffer EC; Fiering SN; Steinmetz NF
Mol Pharm; 2023 Jan; 20(1):500-507. PubMed ID: 36399598
[TBL] [Abstract][Full Text] [Related]
11. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
[TBL] [Abstract][Full Text] [Related]
12. Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.
Mao C; Beiss V; Fields J; Steinmetz NF; Fiering S
Biomaterials; 2021 Aug; 275():120914. PubMed ID: 34126409
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Hepatocellular Carcinoma by Multimodal In Situ Vaccination Using Cryoablation and a Plant Virus Immunostimulant.
Ghani MA; Bangar A; Yang Y; Jung E; Sauceda C; Mandt T; Shukla S; Webster NJG; Steinmetz NF; Newton IG
J Vasc Interv Radiol; 2023 Jul; 34(7):1247-1257.e8. PubMed ID: 36997021
[TBL] [Abstract][Full Text] [Related]
14. Cowpea Mosaic Virus and Natural Killer Cell Agonism for In Situ Cancer Vaccination.
Koellhoffer EC; Steinmetz NF
Nano Lett; 2022 Jul; 22(13):5348-5356. PubMed ID: 35713326
[TBL] [Abstract][Full Text] [Related]
15. The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination Is Unaffected by the Specific Encapsidated Viral RNA.
Jung E; Chung YH; Mao C; Fiering SN; Steinmetz NF
Mol Pharm; 2023 Jul; 20(7):3589-3597. PubMed ID: 37294891
[TBL] [Abstract][Full Text] [Related]
16. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
Sheen MR; Fiering S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
18. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
19. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
[TBL] [Abstract][Full Text] [Related]
20. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
